Ryan D Maynard sold $503k of IOVA
director at IOVANCE BIOTHERAPEUTICS, INC.. 50,000 shares at an average of $10.06, traded Nov 12, 2024, filed Nov 14, 2024.
Score components
- +15RoleDirector
- +18Trade size$503k at market
- +20Share of holdings soldSold 87% of holdings
- 0ClusterNo other insider selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m -8.8%, 3m -37.8%, 6m -79.5%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001104659-24-119195, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Nov 12, 2024 | MOption exercise Common Stock | +50,000 | $7.45 | $373k | 57,500 | Nov 14, 2024 |
| Nov 12, 2024 | SOpen-market sale Common Stock | -50,000 | $10.06 | $503k | 7,500 | Nov 14, 2024 |
| Nov 12, 2024 | MOption exercise Stock Option (right to buy)derivative | -50,000 | $0.00 | $0 | 0 | Nov 14, 2024 |
Related signals
Other insiders at IOVANCE BIOTHERAPEUTICS, INC. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 56Moderate | IOVANCE BIOTHERAPEUTICS, INC. | Daniel Gordon Kirby Chief Commercial Officer | $55k 30,000 shares | - | |
| 48Moderate | IOVANCE BIOTHERAPEUTICS, INC. | Raj K. Puri Chief Regulatory Officer | $9,743 5,600 shares | +3% | |
| 60Notable | IOVANCE BIOTHERAPEUTICS, INC. | Frederick G Vogt Interim CEO & General Counsel | $42k 25,000 shares | +7% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.